Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ARYA Sciences Acquisition Corp IV Market Cap
Based on ratings from 0 stock analysts, the ARYA Sciences Acquisition Corp IV stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for ARYA Sciences Acquisition Corp IV. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
ARYA Sciences Acquisition Corp IV has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that ARYA Sciences Acquisition Corp IV will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ARYD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2021
Staff Count
0
Country
United States
Sector/Industry
Financial Services/Shell Companies
CEO
Mr. Adam Leo Stone
Market Cap
$50.0M
In 2023, ARYD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ARYD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Adagio Medical has completed its business combination with ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors, enhancing its position in catheter ablation technologies.
Why It Matters - The completion of Adagio Medical's merger with ARYA IV indicates growth potential in the catheter ablation market, which may attract investor interest and impact stock performance.
Wed, 14 Feb 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - The combined company anticipates receiving around $42 million from equity and convertible note investors at closing.
Why It Matters - The $42 million funding indicates strong investor confidence, potentially enhancing the company's financial stability and growth prospects, positively impacting stock valuation.
Thu, 24 Feb 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ARYA Sciences Acquisition Corp IV and Amicus Therapeutics have mutually terminated their Business Combination Agreement due to current market conditions, effective immediately.
Why It Matters - The termination of the business combination may signal challenges in market conditions, affecting investor confidence and potentially leading to stock price volatility for both ARYA IV and Amicus.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
